A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
Public ClinicalTrials.gov record NCT04644315. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Open-Label, Single Arm Decentralized Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
Study identification
- NCT ID
- NCT04644315
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Enrollment
- 1 participant
Conditions and interventions
Conditions
- Brain Neoplasms
- Bronchial Neoplasms
- Carcinoma, Bronchogenic
- Central Nervous System
- Cholangiocarcinoma
- Colonic Diseases
- Colorectal Neoplasms
- Digestive System Diseases
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Gastrointestinal Neoplasms
- Head and Neck Neoplasms
- Intestinal Diseases
- Intestinal Neoplasms
- Lymphoma, Large-Cell, Anaplastic
- Melanoma
- Neoplasms
- Neoplasms by Site
- Neuroendocrine Tumors
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Respiratory Tract Diseases
- Respiratory Tract Neoplasms
- Salivary Gland Neoplasms
- Sarcoma
- Thoracic Neoplasms
- Thyroid Cancer, Papillary
- Thyroid Neoplasms
Interventions
- Alectinib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 23, 2021
- Primary completion
- May 15, 2022
- Completion
- May 15, 2022
- Last update posted
- Aug 6, 2023
2021 – 2022
United States locations
- U.S. sites
- 29
- U.S. states
- 9
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Science 37, Inc | Culver City | California | 90230 | — |
| Science 37-Basem; Dept 004- Basem | Culver City | California | 90230 | — |
| Science 37-Beg; Dept 001 Dr. M. Beg | Culver City | California | 90230 | — |
| Science 37-Cannon; Dept 002-Cannon | Culver City | California | 90230 | — |
| Science 37-Kurzrock; Dept 005-Kurzrock | Culver City | California | 90230 | — |
| Science 37-Thomas; Dept 006-Thomas | Culver City | California | 90230 | — |
| Homebased Telemedicine | Los Angeles | California | 90013 | — |
| Homebased Telemedicine | Sacramento | California | 95814 | — |
| Homebased Telemedicine | San Diego | California | 92101 | — |
| Homebased Telemedicine | San Francisco | California | 94104 | — |
| Homebased Telemedicine | San Jose | California | 95110 | — |
| Homebased Telemedicine | Jacksonville | Florida | 32202 | — |
| Homebased Telemedicine | Miami | Florida | 33132 | — |
| Homebased Telemedicine | Orlando | Florida | 32801 | — |
| Homebased Telemedicine | Tampa | Florida | 33601 | — |
| Homebased Telemedicine | Fort Wayne | Indiana | 46802 | — |
| Homebased Telemedicine | Indianapolis | Indiana | 46202 | — |
| Homebased Telemedicine | Minneapolis | Minnesota | 55401 | — |
| Homebased Telemedicine | Saint Paul | Minnesota | 55155 | — |
| Homebased Telemedicine | St Louis | Missouri | 63103 | — |
| Homebased Telemedicine | Buffalo | New York | 14202 | — |
| Homebased Telemedicine | New York | New York | 10038 | — |
| Homebased Telemedicine | Philadelphia | Pennsylvania | 19103 | — |
| Homebased Telemedicine | Pittsburgh | Pennsylvania | 15282 | — |
| Homebased Telemedicine | Austin | Texas | 78701 | — |
| Homebased Telemedicine | Dallas | Texas | 75202 | — |
| Homebased Telemedicine | Houston | Texas | 77002 | — |
| Homebased Telemedicine | Richmond | Virginia | 23220 | — |
| Homebased Telemedicine | Virginia Beach | Virginia | 23451 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04644315, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 6, 2023 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04644315 live on ClinicalTrials.gov.